Cardiac hypertrophy, fibrosis and inflammation lead to adverse cardiac remodelling in heart failure, and this is a key contributor to its severity.32 Some pre-clinical and clinical studies have demonstrated a role for SGLT2-inhibitor therapies in reversing adverse cardiac remodelling.33 34 Although this effect has been observed in patients with type 2 diabetes and left ventricular hypertrophy, it has not been seen in patients with heart failure.35 36 This is intriguing, particularly, since the majority of its cardiovascular benefits have been around heart failure outcomes. Here, SLC5A2 is linked to type 2 diabetes mellitus.